Job Description

　　Job Duties:

　　Provide statistical input including development of study design, formulating study endpoints, implementing appropriate statistical analysis methods Perform sample size and power calculations Review statistical section of study reports Prepare and maintain statistical analysis plans (SAP) for individual studies, ISS and ISE ensuring that appropriate statistical methods are utilized Create shells (mock-ups) for tables, listings, and figures Represent Biostatistics in study and project team meetings Collaborate with Statistical Programming on the implementation of the SAP Conduct statistical analyses and perform SAS programming, as needed Provide statistical analyses support to publications (e.g. abstracts, presentations and posters, manuscripts) Assist in the development of departmental processes and procedures. Maintain study documentation of statistical analyses and supportive documents Ensure adherence to industry standards and regulatory requirements, including but not exclusive to Good Clinical Practices (GCP) and ICH guideline on Statistical Principles for Clinical Trials Ensure that Glaukos statistical/programming policies, guidelines, and procedures are followed Basic knowledge of standards for statistical applications in the conduct of Clinical Research Knowledge of statistical terminology, clinical tests, medical terminology, and protocol designs Maintains expertise in state-of-the-art statistical methodology Ability to learn and utilize new methodologies

　　About Us

　　Founded in 1998, Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases.

　　Our company was the first company to bring to market Micro-Invasive Glaucoma Surgery (MIGS), the micro-invasive procedure which revolutionized the treatment and management of glaucoma. In 2012, we launched our first MIGS device-the iStent®-in the United States, followed by our next-generation iStent inject ® device in September 2018 and iStent inject ® W in September 2020.

　　In November 2019, Glaukos acquired Avedro, maker of the first and only FDA-approved cross-linking technology for progressive keratoconus. And we continue to seek to leverage our platform technologies to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies for glaucoma, corneal health, and retinal diseases.

　　Our company completed an initial public offering in June of 2015, and our shares are traded on the New York Stock Exchange under the ticker symbol "GKOS". Our global headquarters is located in San Clemente, California with additional locations in Waltham and Burlington, Massachusetts.

　　Glaukos Corporation is an Equal Opportunity/Affirmative Action Employer. All qualified applicants will receive consideration for employmentwithout regard to race, color, religion, sex including sexual orientation and genderidentity, national origin, disability, protected Veteran Status, or any othercharacteristic protected by applicable federal, state, or local law.